Alcami Corporation, a US-based contract development and manufacturing organisation (CDMO), announced on Monday that it has named Bill Humphries as its new CEO effective 5 June 2023.

Humphries, who is also joining the company's board of directors, will succeed Patrick Walsh, who has announced his retirement.

Humphries has served in various executive leadership roles, which included CEO at Isosceles Pharmaceuticals, president and group company chairman of Ortho-Dermatologics, CEO of Merz North America, president of Stiefel, a GSK Company and vice president of US Skincare at Allergan Pharmaceuticals. He has held the position of chairman of the board at Clearside Biomedical, executive chairman of Strata Skin Sciences, and a member of the board of directors at Aclaris Therapeutics, PhaseBio Pharmaceuticals, SKNV, and Bryn Pharmaceuticals.